← Back to Search

Decision-Making Support for Prostate Cancer Screening (PSA Trial)

N/A
Waitlist Available
Led By Roshan Bastani, PhD
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Latino men
Not having BPH (prostate inflammation)
Must not have
Younger than 50 or older than 70 years old
Having had prostate cancer previously
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing an intervention to increase inform decision-making in Latino men regarding prostate cancer screening. The intervention is an interactive presentation on prostate cancer, given to small groups of men. The investigators hope that this will increase knowledge of prostate cancer, communication about the disease, and screening rates.

Who is the study for?
This trial is for Latino men aged 50-70 in Los Angeles who have never had prostate cancer or a PSA test in the last year, and do not currently have prostate issues like pain during urination. Men with previous prostate surgery, biopsy, or outside the age range are excluded.
What is being tested?
The study tests if an interactive session discussing prostate cancer screening can improve decision-making among participants compared to just receiving printed material. The impact on knowledge and screening rates will be assessed through follow-ups.
What are the potential side effects?
Since this trial involves educational sessions rather than medical treatments, there are no direct side effects related to drugs or interventions typically associated with clinical trials.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a Latino man.
Select...
I do not have prostate inflammation.
Select...
I have never had prostate cancer.
Select...
I do not have prostate issues like pain during urination or frequent urges to urinate.
Select...
I am between 50 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am either under 50 or over 70 years old.
Select...
I have had prostate cancer before.
Select...
I have had surgery to remove my prostate.
Select...
I am experiencing symptoms like pain during urination, blood in my urine, or frequent urination.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2Experimental Treatment1 Intervention
Printed material regarding general prostate cancer information provided.
Group II: 1Experimental Treatment1 Intervention
Educational small group session regarding prostate cancer
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Printed Material
2007
N/A
~300

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
34,188 Total Patients Enrolled
30 Trials studying Prostate Cancer
1,484 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,022,164 Total Patients Enrolled
515 Trials studying Prostate Cancer
331,954 Patients Enrolled for Prostate Cancer
Roshan Bastani, PhDPrincipal InvestigatorUniversity of California, Los Angeles
4 Previous Clinical Trials
73,407 Total Patients Enrolled

Media Library

Intervention Session Clinical Trial Eligibility Overview. Trial Name: NCT00761124 — N/A
Prostate Cancer Research Study Groups: 1, 2
Prostate Cancer Clinical Trial 2023: Intervention Session Highlights & Side Effects. Trial Name: NCT00761124 — N/A
Intervention Session 2023 Treatment Timeline for Medical Study. Trial Name: NCT00761124 — N/A
~4 spots leftby Feb 2025